These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276 [TBL] [Abstract][Full Text] [Related]
27. [Angiogenesis inhibitors: mechanism of action and nephrotoxicity]. Clou E; Luque Y Nephrol Ther; 2022 Feb; 18(1):1-6. PubMed ID: 34838486 [TBL] [Abstract][Full Text] [Related]
28. Plasma exchange for treatment of a therapy-related thrombotic microangiopathy in a patient with advanced hepatocellular carcinoma-A case report. Stortz M; Shmanko K; Kraus D; Gairing S; Boedecker-Lips S; Förster F; Weinmann A; Weinmann-Menke J Clin Case Rep; 2023 Nov; 11(11):e8124. PubMed ID: 37953891 [TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic Therapy for Diabetic Nephropathy. Tanabe K; Maeshima Y; Sato Y; Wada J Biomed Res Int; 2017; 2017():5724069. PubMed ID: 28835895 [TBL] [Abstract][Full Text] [Related]
30. Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease. Sun PP; Yu XJ; Wang SX; Zhou XJ; Qu L; Zhang F; Ma YY; Liu G; Yang L Nephrology (Carlton); 2020 Feb; 25(2):125-134. PubMed ID: 31264312 [TBL] [Abstract][Full Text] [Related]
31. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439 [TBL] [Abstract][Full Text] [Related]
32. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Cosmai L; Gallieni M; Liguigli W; Porta C J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025 [TBL] [Abstract][Full Text] [Related]
33. Renal involvement in preeclampsia: similarities to VEGF ablation therapy. Müller-Deile J; Schiffer M J Pregnancy; 2011; 2011():176973. PubMed ID: 21494322 [TBL] [Abstract][Full Text] [Related]
34. [Management of side effects of targeted therapies in renal cancer: nephrological side effects]. Izzedine H; Négrier S; Neuzillet Y; Zini L Bull Cancer; 2011; 98(3 Suppl):S7-S18. PubMed ID: 25819129 [TBL] [Abstract][Full Text] [Related]
35. Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis. Robinson CH; Hart-Matyas M; Morgenstern DA; Noone D; Campisi P Ann Otol Rhinol Laryngol; 2024 Jan; 133(1):119-123. PubMed ID: 37439024 [TBL] [Abstract][Full Text] [Related]
36. Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice. Del Cura Mar P; Carballés MJC; Sastre-Ibáñez M Indian J Ophthalmol; 2023 Aug; 71(8):3091-3094. PubMed ID: 37530286 [TBL] [Abstract][Full Text] [Related]
37. Lenvatinib-related renal microangiopathy: a case series. Delsante M; Monroy-Trujillo JM; Carter-Monroe N; Ball DW; Rosenberg AZ Virchows Arch; 2022 Feb; 480(2):467-473. PubMed ID: 33959820 [TBL] [Abstract][Full Text] [Related]
39. A rare case of renal thrombotic microangiopathy associated with Castleman's disease. Mutneja A; Cossey LN; Liapis H; Chen YM BMC Nephrol; 2017 Feb; 18(1):57. PubMed ID: 28183278 [TBL] [Abstract][Full Text] [Related]
40. Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy. Nishi K; Sato M; Ogura M; Okutsu M; Ishikura K; Kamei K BMC Nephrol; 2020 Aug; 21(1):323. PubMed ID: 32746791 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]